Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

In this work, Planas et al. report that Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 escape neutralization from monoclonal antibodies, and sera from vaccinated individuals with or without Omicron BA.1/2 or BA.5 breakthrough infection.

Bibliographic Details
Main Authors:	Delphine Planas, Timothée Bruel, Isabelle Staropoli, Florence Guivel-Benhassine, Françoise Porrot, Piet Maes, Ludivine Grzelak, Matthieu Prot, Said Mougari, Cyril Planchais, Julien Puech, Madelina Saliba, Riwan Sahraoui, Florent Fémy, Nathalie Morel, Jérémy Dufloo, Rafael Sanjuán, Hugo Mouquet, Emmanuel André, Laurent Hocqueloux, Etienne Simon-Loriere, David Veyer, Thierry Prazuck, Hélène Péré, Olivier Schwartz
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-02-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-36561-6

Similar Items

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
by: Airu Zhu, et al.
Published: (2023-03-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
by: Delphine Planas, et al.
Published: (2024-03-01)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
by: Tomokazu Tamura, et al.
Published: (2023-07-01)

Omicron subvariant BA.5 efficiently infects lung cells
by: Markus Hoffmann, et al.
Published: (2023-06-01)

Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
by: Yu WU, Jue LIU, Min LIU, Wannian LIANG
Published: (2022-10-01)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
by: Hung Fu Tseng, et al.
Published: (2023-01-01)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
by: Rahatul Islam, et al.
Published: (2023-08-01)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
by: Frederik Plesner Lyngse, et al.
Published: (2022-09-01)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
by: Danyi Ao, et al.
Published: (2023-04-01)

High Transmission Rates of Early Omicron Subvariant BA.2 in Bangkok, Thailand
by: Sininat Petcharat, et al.
Published: (2023-01-01)

Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou
by: Feng Li, et al.
Published: (2023-04-01)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
by: Mingxi Li, et al.
Published: (2022-12-01)

Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes
by: Rayhane Nchioua, et al.
Published: (2022-12-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
by: Hiam Chemaitelly, et al.
Published: (2022-06-01)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
by: Alexander Wilhelm, et al.
Published: (2022-08-01)

Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases
by: Marija Gjorgjievska, et al.
Published: (2022-04-01)

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
by: Khadija Khan, et al.
Published: (2023-12-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
by: Aiste Dijokaite-Guraliuc, et al.
Published: (2022-11-01)

Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau
by: Cong Xu, et al.
Published: (2023-01-01)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
by: Naoyuki Miyashita, et al.
Published: (2023-05-01)

Protection against SARS-CoV-2 BA.4 and BA.5 subvariants via vaccination and natural infection: A modeling study
by: Yuta Okada, et al.
Published: (2023-01-01)

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
by: Jumpei Ito, et al.
Published: (2023-05-01)

Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
by: Li-Teh Liu, et al.
Published: (2023-10-01)

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection
by: Jingyun Yang, et al.
Published: (2023-06-01)

Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data
by: Antonio Russo, et al.
Published: (2024-01-01)

Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding
by: Marko Popovic
Published: (2022-10-01)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
by: Alina Seidel, et al.
Published: (2023-04-01)

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.
by: Srilekha Sridhara, et al.
Published: (2023-01-01)

The SARS-CoV-2 BA.2.86 subvariant: A new challenge in the ongoing pandemic
by: Prakasini Satapathy, et al.
Published: (2024-01-01)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
by: Xinling Wang, et al.
Published: (2023-11-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells
by: Jérémy Dufloo, et al.
Published: (2022-02-01)

Renewed global threat by the novel SARS-CoV-2 variants ‘XBB, BF.7, BQ.1, BA.2.75, BA.4.6’: A discussion
by: Ranjan K. Mohapatra, et al.
Published: (2022-12-01)

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
by: Jianpeng Cai, et al.
Published: (2024-12-01)

Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children
by: Xiaohe Li, et al.
Published: (2022-06-01)

HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells
by: Cyril Planchais, et al.
Published: (2019-04-01)

A Target or the Next XCov23 Campaign: KPD 1930+2752
by: Charpinet S., et al.
Published: (2003-03-01)

Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants
by: Selene Zárate, et al.
Published: (2023-01-01)